Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCH NASDAQ:GRCL NASDAQ:ITOS NASDAQ:PHAR NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/AITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$13.72-6.6%$12.09$7.31▼$17.08$953.32M0.056,677 shs12,949 shsPHVSPharvaris$23.46+1.1%$21.88$11.51▼$26.33$1.23B-2.883,943 shs52,608 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.36%-2.36%-8.82%+9.73%GRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%ITOSiTeos Therapeutics0.00%0.00%+0.40%+0.50%-39.22%PHARPharming Group0.00%-2.97%+26.01%+29.95%+95.73%PHVSPharvaris0.00%+0.65%+4.04%+36.79%+10.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/AITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$13.72-6.6%$12.09$7.31▼$17.08$953.32M0.056,677 shs12,949 shsPHVSPharvaris$23.46+1.1%$21.88$11.51▼$26.33$1.23B-2.883,943 shs52,608 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.36%-2.36%-8.82%+9.73%GRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%ITOSiTeos Therapeutics0.00%0.00%+0.40%+0.50%-39.22%PHARPharming Group0.00%-2.97%+26.01%+29.95%+95.73%PHVSPharvaris0.00%+0.65%+4.04%+36.79%+10.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/AGRCLGracell Biotechnologies 0.00N/AN/AN/AITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsidePHARPharming Group 3.00Buy$30.00112.07% UpsidePHVSPharvaris 2.80Moderate Buy$34.0045.11% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, ITOS, FNCH, GRCL, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$55.00 ➝ $52.008/7/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$12.00 ➝ $11.007/21/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $10.50(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AGRCLGracell Biotechnologies$60K12,415.83N/AN/A$2.95 per share3.47ITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91PHARPharming Group$297.20M3.26$0.07 per share198.04$3.25 per share4.35PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AGRCLGracell Biotechnologies-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/AITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A471.53N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)Latest PHVS, ITOS, FNCH, GRCL, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGRCLGracell BiotechnologiesN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87GRCLGracell Biotechnologies0.027.737.73ITOSiTeos TherapeuticsN/A7.537.53PHARPharming Group0.382.792.07PHVSPharvarisN/A8.338.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%GRCLGracell BiotechnologiesN/AITOSiTeos Therapeutics97.16%PHARPharming Group0.03%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%GRCLGracell Biotechnologies28.00%ITOSiTeos Therapeutics14.20%PHARPharming Group2.07%PHVSPharvarisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataGRCLGracell Biotechnologies31472.68 million52.33 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionablePHVSPharvaris3052.29 millionN/ANot OptionablePHVS, ITOS, FNCH, GRCL, and PHAR HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Shares Up 8.3% - Here's What HappenedSeptember 11, 2025 | marketbeat.comPharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comPharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.6% - Here's WhySeptember 4, 2025 | marketbeat.comPharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.9% - What's Next?August 27, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 27, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Upgraded to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 6.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Short Interest UpdateAugust 20, 2025 | marketbeat.comPharvaris Advances Clinical Pipeline with Strong FinancialsAugust 20, 2025 | msn.comWhat is Leerink Partnrs' Estimate for Pharvaris Q3 Earnings?August 19, 2025 | marketbeat.comCantor Fitzgerald Increases Earnings Estimates for PharvarisAugust 17, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)August 17, 2025 | marketbeat.comWedbush Predicts Pharvaris' FY2029 Earnings (NASDAQ:PHVS)August 16, 2025 | marketbeat.comJMP Securities Lowers Pharvaris (NASDAQ:PHVS) Price Target to $52.00August 15, 2025 | marketbeat.comPharvaris price target lowered to $52 from $55 at Citizens JMPAugust 13, 2025 | msn.comPharvaris Reports Q2 2025 Financials and Advances Phase 3 StudiesAugust 12, 2025 | msn.comPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | taiwannews.com.twTPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comPharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutionsJuly 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, ITOS, FNCH, GRCL, and PHAR Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$12.40 -0.27 (-2.13%) As of 09/12/2025 03:50 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Gracell Biotechnologies NASDAQ:GRCLGracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.iTeos Therapeutics NASDAQ:ITOS$10.15 0.00 (0.00%) As of 08/29/2025iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Pharming Group NASDAQ:PHAR$13.72 -0.97 (-6.57%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Pharvaris NASDAQ:PHVS$23.46 +0.26 (+1.10%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
